Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT05212727
Other study ID # ETNA-NDHC
Secondary ID
Status Suspended
Phase
First received
Last updated
Start date April 15, 2022
Est. completion date May 3, 2024

Study information

Verified date March 2024
Source Innodem Neurosciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.


Recruitment information / eligibility

Status Suspended
Enrollment 300
Est. completion date May 3, 2024
Est. primary completion date May 3, 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged 18 years old and above - A score of = 26 on the Montreal Cognitive Assessment (MoCA) - Able to provide informed consent - Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc are permitted). Exclusion Criteria: - Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control. - Evidence or history of significant neurological disorder (e.g. MS, PD, ALS, Dementia) - Use of prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics, and anticonvulsants. - Diagnosed with an active substance use disorder. - History of stroke. - Recent traumatic brain injury (within the last 6 months).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Eye-tracking
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.

Locations

Country Name City State
Canada Innodem Neurosciences Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Innodem Neurosciences

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symbol Digit Modalities Test (SDMT) score, one time, at the day of enrolment. The SDMT is used to assess divided attention, visual scanning, tracking and motor speed. Using a reference key, the examinee has 90 seconds to pair specific numbers with given geometric figures. Scoring involves summing the number of correct substitutions within the 90 second interval. Baseline
Secondary Brief International Cognitive Assessment for MS (BICAMS) score, one time, at the day of enrolment. The BICAMS is a battery of tests recommended by multiple sclerosis (MS) experts to monitor MS-related cognitive impairment. It includes the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) Baseline
Secondary Multiple sclerosis functional composite (MSFC) score, one time, at the day of enrolment. A clinical trial outcome measure of assessing the severity of multiple sclerosis (MS) primarily. used in research. The score is based on a combination of timed tests of walking, arm function, and cognitive ability. It is a three-part, standardized, quantitative, assessment instrument for use in clinical studies, particularly clinical trials, of MS. The MSFC can produce scores for each of the three individual measures as well as a composite score. Baseline
Secondary The Montreal Cognitive Assessment (MoCA) score, one time, at the day of enrolment. The Montreal Cognitive Assessment (MoCA) is a brief 30-question cognitive screening test designed to assist Health Professionals in the detection of mild cognitive impairment and Alzheimer's disease. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal.
Baseline
Secondary The Mini-Mental State Exam (MMSE) score, one time, at the day of enrolment. The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly, it includes tests of orientation, attention, memory, language and visual-spatial skills. It consists of a series of questions and tests that can be used by clinicians to help diagnose dementia and to help assess its progression and severity. Baseline
Secondary The Controlled Oral Word Association Test (COWAT) score, one time, at the day of enrolment. The Controlled Oral Word Association Test from the Halstead-Reitan Neuropsychological Battery is a verbal fluency test in which participants are asked to say as many words as possible from a given category and in a specified timeframe (typically 60 seconds). Baseline
Secondary The Trail Making Test (TMT) Parts A & B score, one time, at the day of enrolment. The Trail Making Test (TMT) is a neuropsychological test that provides information on visual search, scanning, speed of processing, mental flexibility and executive functions. The TMT consists of two parts. TMT-A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for TMT-B except the person must alternate between numbers and letters (e.g., 1, A, 2, B, 3, C, etc.). The score on each part represents the amount of time required to complete the task. Baserline
Secondary The Hopkins Verbal Learning Test-Revised (HVLT-R) score, one time, at the day of enrolment. The Hopkins Verbal Learning Test (HVLT-R) is a neuropsychological test that provides information on verbal learning and memory. The assessment consists of memorization of a list of words to test the ability to recall immediately after memorization (immediate recall) and after a 20-minute delay (delayed recall). Baseline
Secondary The Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), one time, at the day of enrolment. The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), currently in its third version, is a questionnaire that evaluates patients' self-reported perceptions of their cognitive abilities and the effects of these cognitive changes on their Health-related quality of life (HRQOL). Baseline
Secondary The Beck Anxiety Inventory (BAI), one time at the day of enrolment. The Beck Anxiety Inventory (BAI) consists of 21 self-reported items (four-point scale) used to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63: minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63). Baseline
See also
  Status Clinical Trial Phase
Completed NCT01589289 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC Phase 3
Completed NCT00010881 - Oregon Center for Complementary and Alternative Medicine in Neurological Disorders N/A
Recruiting NCT04461821 - Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
Completed NCT04094571 - Muscle Delay Characterization N/A
Completed NCT04072536 - Evaluation on Standardized Circuits of the Interest of a Robotic Module of Assistance to the Driving N/A
Recruiting NCT02795052 - Neurologic Stem Cell Treatment Study N/A
Completed NCT02219269 - A Complex Contraception Registry N/A
Completed NCT00122174 - Stress-Busting Program for Caregivers of Patients With Neruological Diseases N/A
Recruiting NCT01524276 - Product Surveillance Registry
Completed NCT00532571 - Effects of Coenzyme Q10 in PSP and CBD Phase 2/Phase 3
Completed NCT05830981 - Valproic Acid Use in Patients With Neurological Disorders
Completed NCT01754168 - Amyloid Beta and Cognition in Parkinson Disease N/A
Completed NCT02780531 - Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases
Completed NCT01858350 - Comparison of the Effectiveness of CAM Therapies in Pediatric Patients Undergoing Sedation N/A
Recruiting NCT01266382 - The Effect of AposTherapy on the Level of Pain, Function and Quality of Life in Patients With Neuro-muscular and Neurological Disorders N/A